Atezolizumab Plus Cabozantinib Shows Promising Early Results in ccRCC
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.
Urology Conferences
Gene Expression Signatures May Be Predictive for Nivolumab in ccRCC
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Gene Signatures Are Potential Biomarkers for ccRCC
Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Gene Signatures May Predict Response to Combination ICIs in ccRCC
Gene signatures were associated with response rate to nivolumab plus ipilimumab among patients with ccRCC, according to results of a phase 2 trial.
Radiologic PFS Benefit Observed for Addition of AKT Inhibitor to Abiraterone in Metastatic CRPC
Loss of the tumor suppressor PTEN, a negative prognostic factor in metastatic CRPC, is associated with dysregulation of the PI3K–AKT–mTOR pathway.
First-Line Avelumab Maintenance Ups Survival in Urothelial Carcinoma
Avelumab improves overall and progression-free survival among patients with unresectable locally advanced or metastatic urothelial carcinoma whose disease has not progressed while on first-line chemotherapy.
Two-Drug Combo Superior to Sunitinib as First-Line Therapy for Advanced RCC
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Positive PSMA PET/CT at Biochemical Recurrence Predicts PCa Progression
In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression.
Severe Nocturia Linked to CKD in Men
In a Japanese study, certain men with chronic kidney disease had greater risks for 3 or more nightly voids.
Sarcomatoid Features in mRCC Predict Worse Survival After Cytoreductive Nephrectomy
Patients who have metastatic renal cell carcinoma with sarcomatoid differentiation in the primary tumor have an increased risk for death following cytoreductive nephrectomy, study found.
-
Loading...
-
Loading...
Next post in EAU Congress
